Corcept Therapeutics said on Monday its experimental drug in combination with chemotherapy helped delay progression of a type ...
Corcept Therapeutics said on Monday its experimental combination ovarian cancer drug improved survival in patients with a ...
A new drug tested in a phase 3 trial showed significant improvement in patients with treatment-resistant ovarian cancer.
A woman's story of literal strength shows how ovarian cancer can be missedāand the lighthearted recovery milestone every care ...
Anixa Biosciences Receives Notice of Allowance from USPTO for Ovarian Cancer Vaccine. Anixa Biosciences, Inc. March 24, 2025.
The first patient was dosed in a phase 3 trial of IBI354 for platinum-resistant ovarian cancer with HER2 expression.
New phase 3 data provide reassurance on safety, tolerability, and overall benefit-risk of mirvetuximab soravtansine (Elahere) ...
Anixa Biosciences (ANIX) announced that the United States Patent and Trademark Office, USPTO, has issued a Notice of Allowance for a key patent ...
Corcept Therapeutics (CORT.O), opens new tab said on Monday its experimental drug in combination with chemotherapy helped delay progression of a type of ovarian cancer in a late-stage trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback